Kiniksa Pharmaceuticals International, plc
KNSA
Rang in aandelen
#2871
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aandeelprijs
$83.13
Marktkapitalisatie
$6.49B
Verandering (1 dag)
4.59%
Verandering (1 jaar)
113.21%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Categorie
Healthcare
Winst voor Kiniksa Pharmaceuticals International, plc (KNSA)
Winst in Jun 2026 TTM: $114.25M
Volgens de meest recente financiële verslagen van Kiniksa Pharmaceuticals International, plc bedraagt de huidige winst van het bedrijf $114.25M. In 2023 behaalde het bedrijf een winst van $-16.65M, een daling ten opzichte van de winst van 2022, die $11.03M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Kiniksa Pharmaceuticals International, plc van 2016 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -76.92% |
US
|
